Chronic Spontaneous Urticaria (CSU) Epidemiology Forecast Report 2022-2032: Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan - ResearchAndMarkets.com

The "Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Chronic Spontaneous Urticaria- Epidemiology Forecast to 2032' report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Currently, there are a lot of clinical trials ongoing in Chronic Spontaneous Urticaria. Novartis' Ligelizumab, a monoclonal anti-IgE antibody has shown superior efficacy over Omalizumab in phase2b and is currently being evaluated in phase 3 trial. Sanofi and Regeneron's Dupixent (dupilumab), already approved in atopic dermatitis is being evaluated in phase III for Chronic Spontaneous Urticaria. Various other emerging drugs in various phases of trials are Rilzabrutinib (Sanofi/Regeneron), Remibrutinib (Novartis), Benralizumab (AstraZeneca), Fenebrutinib (Genentech), KPL-716 (Kiniksa Pharma), UB-221 (United BioPharma), Mepolizumab (GlaxoSmithKline), AK002 (Allakos).

However, there are still few unmet needs in the understanding of disease etiology in cases where autoimmunity is ruled out. Quality of life is severely impacted in Chronic Spontaneous Urticaria patients due to unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement.

Patients with Chronic Spontaneous Urticaria often exhibit psychiatric comorbidities. Chronic Spontaneous Urticaria also has a large direct and indirect economic impact due to increased healthcare cost because of continued medication to control symptoms, and frequent, often unanticipated healthcare visits.

Chronic Spontaneous Urticaria Epidemiology

The Chronic Spontaneous Urticaria epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Spontaneous Urticaria epidemiology segmented as Total Prevalent cases of Chronic Spontaneous Urticaria, Gender-specific Cases of Chronic Spontaneous Urticaria, and Age-specific cases of Chronic Spontaneous Urticaria. The report includes the prevalent scenario of Chronic Spontaneous Urticaria in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise-Chronic Spontaneous Urticaria Epidemiology

The epidemiology segment also provides the Chronic Spontaneous Urticaria epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Chronic Spontaneous Urticaria associated in 7MM countries was estimated to be 1,848,622 cases in 2021 and expected to increase at a CAGR of 0.33% for the study period, i.e., 2019-2032.

• As per the estimates, United States has the highest prevalence population of Chronic Spontaneous Urticaria in the 7MM.

Among the EU5 countries, Germany had the highest prevalent population of Chronic Spontaneous Urticaria. On the other hand Spain had the lowest prevalent population. In 7MM, Spain had the lowest number of cases i.e. 178,389 cases in 2021.

Scope of the Report

• Chronic Spontaneous Urticaria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Chronic Spontaneous Urticaria Epidemiology Report and Model provides an overview of the risk factors and global trends of Chronic Spontaneous Urticaria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Chronic Spontaneous Urticaria in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Spontaneous Urticaria
• The report provides the segmentation of the Chronic Spontaneous Urticaria epidemiology by prevalent cases of Chronic Spontaneous Urticaria in 7MM
• The report provides the segmentation of the Total Prevalent cases of Chronic Spontaneous Urticaria, Gender-specific Cases of Chronic Spontaneous Urticaria, and Age-specific cases of Chronic Spontaneous Urticaria in the 7MM

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2019

3.2. Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2032

4. Executive Summary of Chronic Spontaneous Urticaria

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Clinical Manifestation

5.7. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Patient Population of Chronic Spontaneous Urticaria

6.3. The United States

6.3.1. Assumption and Rationale

6.3.2. Total Prevalent cases of Chronic Spontaneous Urticaria in the United States

6.3.3. Gender-specific Cases of Chronic Spontaneous Urticaria in the United States

6.3.4. Age-specific cases of Chronic Spontaneous Urticaria in the United States

6.4. EU5

6.5. Japan

7. Treatment and Management

7.1. Treatment and Management

7.2. EAACI/GALEN/EDF/WAO guideline

8. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/emcdvv

View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005299/en/